Medications

First report card on biosimilars in oncology

Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin and Herceptin. In a Policy Review in The Lancet Oncology, Y. Tony Yang, a professor ...

Oncology & Cancer

Financial disclosure lacking in publication of clinical trials

A substantial proportion of pharmaceutical industry payments to authors of oncology clinical trials published in major scientific journals are not disclosed, new research shows. The publications focused on clinical trials ...

Oncology & Cancer

Clinical trials show promise in leukemia

Two drugs that target different mutations showed encouraging results in treating leukemia, according to recent clinical trials published in the New England Journal of Medicine (NEJM) and The Lancet Oncology.

Oncology & Cancer

How to implement Advance Care Planning for patients

Emeritus Professor Sheila Payne from the International Observatory on End of Life Care at Lancaster University helped conduct the study commissioned by the European Association for Palliative Care (EAPC) and published in ...

Oncology & Cancer

Better detection may explain higher child cancer numbers: UN

Global childhood cancer rates jumped 13 percent in the decade to 2010 compared to the 1980s, according to a UN-backed study released Wednesday that says the increase may be due in part to improved detection.

page 1 from 11